Lumenis Unveils the Pulse™ 30H, the State-of-the-Art Laser Solution Designed to Address Any Type and Size of Stone
YOKNEAM, Israel, 2016-03-11 09:00 CET (GLOBE NEWSWIRE) -- Lumenis Ltd., the world’s largest energy-based medical device company for surgical, aesthetic and ophthalmic applications, announced the launch of Lumenis Pulse 30H, the new addition to Lumenis’ comprehensive Urology portfolio, at the European Association of Urology (EAU) Congress, taking place March 11-15, 2016 in Munich.
A photo accompanying this announcement is available athttp://www.globenewswire.com/NewsRoom/AttachmentNg/eebaf25f-74af-4dc8-9177-54732e90b31d
As the newest offering in its category, thePulse 30Hsystem has an energy per pulse of up to 5J, the highest of its kind, along with a repetition rate of 25Hz. These features contribute to reduced procedure duration, higher stone fragmentation rate and minimal retropulsion. These capabilities set it apart from competition and increase the variety of stone types and sizes addressed during procedures.
“I was extremely impressed by the comprehensive solution the Lumenis Pulse 30H provides in addressing stones of any type and size, as well as tumors,” said Dr. Guido Giusti, Urologist, Head of European Training Center in Endourology, Ospedale San Raffaele-Turro, Milan, Italy. “The system along with its fibers has definitely set a new standard in the mid/low power range of stone systems.”
Offering optimal user experience, the Lumenis Pulse 30H features an intuitive user interface, efficient and flexible space-saving design offered in tower or desktop, green aiming bean in five adjustment options for enhanced endoscopic visibility and a system’s setting summary report for 10 last treatments. Additionally, the Pulse 30H is aligned with Lumenis fibers, maximizing the fiber’s durability and energy utilization during procedures.
“With a history of innovation in the urology community, Lumenis’ holmium lasers and delivery devices are the standard of care in urology. Through our unique Pulse 120H product and the latest additions of Pulse 100H and Pulse 50H, we provide state-of-the-art offerings to various market segments,” said Tzipi Ozer-Armon, CEO of Lumenis. “By adding the Pulse 30H to our family of urology solutions, we are now offering a new best-in-class product in the low-watt segment, and look forward to continuing our commitment to deliver premium products to drive better treatment standards, and ultimately, enhance the quality of care for patients.”
To learn more about the Pulse 30H and Lumenis’ innovative laser technology, please visit the Lumenis booth #E10.
Additionally, Lumenis invites conference attendees to join a holmium panel discussion, “The importance of Holmium High Power / High Repetition to address BPH and stones,” with Professor Olivier Traxer, University of Paris 6th. Panelists will include: Mark Cynk, MD, Spire Turnbridge Wells Hospital; Rick Popert, MD, Guy’s and St. Thomas’ NHS Foundation Trust; Patrick De Geeter,MD, Klinikum Kassel; Tev Aho, MD, Nuffield Health Cambridge Hospital; Mark Leo, MD, Urology Specialists of Nevada; and Guido Giusti, MD, Ospedale San Raffaele-Turro. The panel will be held on Saturday, March 12, 6:00 - 7:30 PM in Room 13B (ICM, Level 1). Instructional courses on the Holmium laser techniques for BPH and stones are provided by Lumenis during EAU. For more information about Lumenis events at EAU, please visit:http://www.lumenis.com/Solutions/Surgical/News/Events/lumenis-at-eau16.
Lumenis is a global leader in the field of minimally-invasive clinical solutions for the Surgical, Ophthalmology and Aesthetic markets, and is a world-renowned expert in developing and commercializing innovative energy-based technologies, including Laser, Intense Pulsed Light (IPL) and Radio-Frequency (RF). For nearly 50 years, Lumenis' ground-breaking products have redefined medical treatments and have set numerous technological and clinical gold-standards. Lumenis has successfully created solutions for previously untreatable conditions, as well as designed advanced technologies that have revolutionized existing treatment methods. For more information visit:www.lumenis.com
For further information:
Lazar Partners Ltd.
Information om Globenewswire
Følg pressemeddelelser fra Globenewswire
Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Globenewswire
GlobeNewswire, Inc.26.5.2018 07:01 | pressemeddelelse
GlobeNewswire Test Release
Virgin Pulse25.5.2018 14:01 | pressemeddelelse
VIRGIN PULSE ANNOUNCES INDUSTRY-LEADING GDPR COMPLIANCE
Elemica24.5.2018 18:20 | pressemeddelelse
Elemica Reports Double Digit Network Growth and Announces New Product Innovations in First Quarter 2018
SNOMED International24.5.2018 15:17 | pressemeddelelse
Luxembourg Announced as SNOMED International's Newest Member
SEMAFO Inc.24.5.2018 14:02 | pressemeddelelse
SEMAFO Signs Underground Mining Services Contract with AUMS
Merus N.V.24.5.2018 13:01 | pressemeddelelse
Merus Announces First Patient Dosed in Phase 1 Clinical Trial of MCLA-158 in Patients with Solid Tumors
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum